Evaxion A/S (NASDAQ:EVAX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Evaxion A/S (NASDAQ:EVAX) from a hold rating to a buy rating in a research report report published on Saturday.

Other equities research analysts also recently issued research reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Evaxion A/S in a research report on Friday, January 9th. HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of Evaxion A/S in a report on Monday, March 9th. JonesTrading began coverage on Evaxion A/S in a research report on Tuesday, March 10th. They issued a “buy” rating and a $10.00 price objective for the company. Lake Street Capital dropped their price objective on Evaxion A/S from $11.00 to $9.00 and set a “buy” rating for the company in a report on Monday, March 9th. Finally, Maxim Group began coverage on shares of Evaxion A/S in a research report on Thursday, February 19th. They set a “buy” rating and a $10.00 target price on the stock. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Evaxion A/S Stock Performance

Shares of Evaxion A/S stock opened at $3.82 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 5.85 and a quick ratio of 5.85. The firm has a 50 day simple moving average of $3.79 and a 200 day simple moving average of $4.66. Evaxion A/S has a fifty-two week low of $1.20 and a fifty-two week high of $12.15. The firm has a market cap of $31.86 million, a P/E ratio of -2.89 and a beta of 0.28.

Evaxion A/S (NASDAQ:EVAX) last posted its quarterly earnings data on Thursday, March 5th. The company reported $0.30 earnings per share for the quarter. Sell-side analysts predict that Evaxion A/S will post -0.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Evaxion A/S

Several institutional investors and hedge funds have recently modified their holdings of the business. SmartHarvest Portfolios LLC bought a new stake in Evaxion A/S during the 4th quarter worth approximately $72,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Evaxion A/S during the 4th quarter worth approximately $38,000. Finally, Wesbanco Bank Inc. bought a new position in Evaxion A/S in the fourth quarter valued at approximately $48,000. 11.04% of the stock is currently owned by institutional investors and hedge funds.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.